Shareholders meeting tomorrow. CEO said they are going to discuss details of signed non-binding agreement apparently for significant milestone payments with some BP. Tomorrow could be very interesting.
Date: Thursday, September 12, 2019 Time: 9:30 a.m. PT / 12:30 p.m. ET Dial In: For audio: 877-407-2986 or 201-378-4916 The live audio webcast may also be accessed via CytoDyn’s corporate website at
========================================================= CytoDyn Inc. (OTC: CYDY) Nader Pourhassan, Ph.D, CEO.
CEO Dr. Nader Pourhassan updates investors on the latest developments for CytoDyn’s lead drug candidate, Leronlimab (PRO 140) for use as a Combination Therapy to treat HIV, and expecting FDA approval in early 2020. Dr. Pourhassan also shares what’s ahead for the company’s pipeline for cancer indications
$CYDY: US HIV only deal closes in 6 weeks, 90M milestone + 50% net royalties, all sales and launch costs on partner. More licensing deals to come in cancer, gvhd, nash, and HIV outside US with people I in data room right now saying they will give an offer.